GUB-UCN2 in Healthy Volunteers, Obesity, and Type 2 Diabetes

• Part 1

  Healthy volunteers randomized to GUB-UCN2 or placebo.

• Part 2

  Males with obesity randomized to GUB-UCN2 or placebo.

• Part 3

  Participants with obesity or T2D randomized to GUB-UCN2 (monotherapy or + SOC) or placebo.

Primary

• Number of Treatment Emergent Adverse Eventsup to week 22

Secondary

• Area Under the Curve from zero to infinityup to week 6

• Area Under the Curve from zero to last measurable concentrationup to week 6

• Time to maximum concentrationup to week 6

• Maximum concentrationup to week 6

• Area Under the Curve over the dosing interval at steady stateup to week 22

• Maximum concentration at steady stateup to week 22

• Time to maximum concentration at steady stateup to week 22